Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Sanofi stock forms a Golden Cross, signaling bullish momentum as Dupixent nears FDA approval for bullous pemphigoid. SNY’s technicals remain strong, with all key moving averages trending higher ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is engaged in discovering, inventing, developing, manufacturing, and commercializing medicines for treating various diseases. Dupixent® has been ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition ... affects older people in the 60 to 80 age bracket. Dupixent (dupilumab) achieved a five-fold greater sustained ...

bullous pemphigoid and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against ...